NCT00051441View on ClinicalTrials.gov

Safety & Efficacy Study of Benzydamine Oral Rinse for the Treatment of Oral Mucositis (Mouth Sores) Resulting From Radiation Therapy for Cancer of the Oral Cavity, Oropharynx, or Nasopharynx

PHASE3CompletedINTERVENTIONAL
Enrollment

605

Participants

Timeline

Start Date

Not specified

Study Completion Date

February 28, 2005

Conditions
StomatitisRadiation Effects
Interventions
DRUG

Benzydamine Hydrochloride 0.15% Oral Rinse

Sponsors

Collaborators (1)

Angelini
All Listed Sponsors
collaborator

Angelini

INDUSTRY

lead

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

INDUSTRY

NCT00051441 - Safety & Efficacy Study of Benzydamine Oral Rinse for the Treatment of Oral Mucositis (Mouth Sores) Resulting From Radiation Therapy for Cancer of the Oral Cavity, Oropharynx, or Nasopharynx | Biotech Hunter | Biotech Hunter